SCNX: Two new therapies launched in 2026 drive revenue growth and pipeline momentum
The session highlighted a data-driven approach to specialty pharma, with two new commercial products launched in 2026 and a robust pipeline targeting large markets. Revenue and market access are expanding, supported by strong IP and a scalable commercial platform.Based on Scienture Holdings, Inc…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.